Tofacitinib Treatment in Patients With Active COVID-19 Infection

被引：2

作者：

Alajlan, Abdulmajeed M. ^{[1
]}

AlZamil, Lama R. ^{[1
]}

Aseri, Amal M. ^{[2
]}

机构：

[1] King Saud Univ, Coll Med, Dept Dermatol, Riyadh, Saudi Arabia

[2] Qassim Univ, Coll Med, Dept Dermatol, Buraydah, Saudi Arabia

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 09期

关键词：

tofacitinib; alopecia areata; jak inhibitor; covid19; jak1; jak3;

D O I：

10.7759/cureus.17957

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alopecia areata is a chronic autoimmune disorder attacking the hair follicle epithelium; hence, causing non-scarring hair loss. It has been found that Janus kinase 3 (JAK3) hyperactivity plays a key role in the pathogenesis of the disease. Tofacitinib is an effective JAK1 and JAK3 inhibitor that can block several cytokines such as IL-2, IL-7, and IL-6. Several studies have demonstrated the efficacy of oral tofacitinib in hair regrowth in alopecia areata patients. With the recent COVID-19 pandemic, it has been advised to withhold JAK inhibitors during the period of active infection due to possible immunosuppression. We herein report two cases of patients with alopecia universalis who continued to use tofacitinib during their active COVID-19 infection and showed no deterioration in their course of illness.

引用

页数：3